Benjamin Hohl, CFO: Enliven Therapeutics ELVN Sell · Filed 06/22

Trade details

Type: Insider sale
Amount: $59,007.41
Shares · price: 1,379 sh · $42.79 a share
Held after: 55,639 sh
Stock: Enliven Therapeutics ELVN
Person: Benjamin HohlCFO
Trade date: 26/06/17
Filed: 26/06/22
Days to filing: 5 days

Sold 2.4% of holdings

Share of holding sold: 2.4%

Enliven Therapeutics trades, last 26 weeks

What else happened in Enliven Therapeutics around then

Filed or reported within 30 days of the trade day · 05/18~07/17

Benjamin Hohl's recent trades

Benjamin HohlCFO
Planned sale10b5-1 planEnliven Therapeutics
Planned sale10b5-1 plan
Enliven Therapeutics
ELVN
$591.2K
12,036 sh
$591.2K
Filed 09/17
Traded 09/17
Benjamin HohlCFO
Sell10b5-1 planEnliven Therapeutics
Sell10b5-1 plan
Enliven Therapeutics
ELVN
$149.2K
3,401 sh
$149.2K
Filed 06/22
Traded 06/17
Benjamin HohlCFO
Sell10b5-1 planEnliven Therapeutics
Sell10b5-1 plan
Enliven Therapeutics
ELVN
$55.4K
1,238 sh
$55.4K
Filed 06/22
Traded 06/17
Benjamin HohlCFO
Planned sale10b5-1 planEnliven Therapeutics
Planned sale10b5-1 plan
Enliven Therapeutics
ELVN
$768.2K
18,054 sh
$768.2K
Filed 06/17
Traded 06/17
Benjamin HohlCFO
SellEnliven Therapeutics
Sell
Enliven Therapeutics
ELVN
$295.8K
10,000 sh
$295.8K
Filed 03/10
Traded 03/06